Bladder cancer risk factors range from lifestyle habits to genetic traits, but smoking stands out as the single biggest contributor. Roughly half of all bladder cancer cases are attributable to cigarette use. The median age at diagnosis is 73, and men are diagnosed about four times more often than women. Understanding what raises your risk can help you recognize whether you fall into a higher-risk category and take steps to reduce exposure where possible.
Smoking Is the Leading Risk Factor
People who have ever smoked have about 2.4 times the risk of developing bladder cancer compared to people who have never smoked. An estimated 51% of bladder cancer cases trace back to cigarette use. The connection is straightforward: your kidneys filter cancer-causing chemicals from tobacco smoke out of your blood and concentrate them in urine, where they sit in direct contact with the bladder lining for hours at a time.
Quitting does lower your risk over time, but former smokers still carry a higher risk than people who never smoked. For people who have already been diagnosed with early-stage bladder cancer, continued smoking is associated with a greater chance of the cancer coming back or progressing. Both the total number of years you’ve smoked and how many cigarettes you smoke per day matter. The longer and heavier the habit, the greater the cumulative damage to the bladder’s inner surface.
Workplace Chemical Exposure
About 25% of bladder cancer cases are linked to occupational exposures. The chemicals most strongly tied to risk are aromatic amines, polycyclic aromatic hydrocarbons, and arsenic. Workers in industries that manufacture dyes, rubber, leather, textiles, and certain plastics have historically faced the highest exposures.
One well-studied chemical, 4-aminobiphenyl, was identified as the probable cause of a bladder cancer cluster at a chemical plant where it appeared as a contaminant in production processes. Another compound, o-toluidine, is used in large quantities (over 7 million pounds per year at some facilities) to manufacture antioxidants and has caused bladder tumors in animal studies. These chemicals can be absorbed through the skin or inhaled as dust and vapor, then filtered through the kidneys into the bladder.
Modern workplace safety regulations have reduced exposure levels significantly since the mid-20th century, but the lag time between exposure and cancer diagnosis can be decades. If you worked in chemical manufacturing, metalworking, painting, hairdressing (due to certain dye chemicals), or trucking (diesel exhaust) years ago, that exposure may still be relevant to your risk today.
Age, Sex, and Ethnicity
Bladder cancer is overwhelmingly a disease of older adults. Half of all diagnoses occur after age 73. It is relatively uncommon before age 55.
Men develop bladder cancer at roughly four times the rate of women. The rate for men across all races is 31.0 per 100,000 people per year, compared to 7.6 for women. This gap likely reflects a combination of historically higher smoking rates among men, greater occupational chemical exposure, and possible hormonal differences in how the bladder responds to carcinogens.
Ethnicity also plays a role. Non-Hispanic white men have the highest incidence at 37.3 per 100,000, followed by non-Hispanic Black men at 19.6. Among women, non-Hispanic white women have the highest rate at 9.1 per 100,000. Asian and Pacific Islander populations have the lowest rates for both sexes. These differences likely reflect a mix of genetic susceptibility, smoking prevalence, occupational patterns, and access to diagnostic care.
Arsenic in Drinking Water
Arsenic is a naturally occurring element that contaminates groundwater in certain regions. The U.S. Environmental Protection Agency sets the regulatory limit for arsenic in municipal water supplies at 10 micrograms per liter, but private wells are not subject to this standard. A National Cancer Institute study found elevated bladder cancer risk in parts of Maine, New Hampshire, and Vermont, where private wells are common and may contain low to moderate arsenic levels.
Globally, regions in South America, South Asia, and parts of the western United States have higher natural arsenic concentrations in groundwater. If you rely on a private well, testing your water for arsenic is a practical step. Filtration systems designed to remove arsenic are available for home use.
Chronic Bladder Irritation and Infections
Long-term inflammation of the bladder lining increases the risk of a specific subtype called squamous cell carcinoma. Chronic urinary tract infections, long-term catheter use, and bladder stones all contribute to this kind of sustained irritation. The mechanism is simple: inflammation damages the protective cell layer inside the bladder, forcing the body to replace those cells repeatedly. Each new round of cell division is another opportunity for mutations to develop.
People who use catheters to empty their bladders are especially vulnerable because the repeated insertion causes ongoing irritation and introduces bacteria, leading to frequent infections. People with congenital bladder abnormalities that prevent complete emptying face a similar cycle of infection and inflammation.
In parts of the Middle East and Africa, a parasitic infection called schistosomiasis causes severe bladder inflammation and dramatically increases bladder cancer rates. This is less of a concern in North America and Europe but is a major risk factor globally.
Prior Cancer Treatments
Two specific cancer treatments raise the risk of later developing bladder cancer. Cyclophosphamide, a chemotherapy drug used to treat lymphomas, leukemias, and some autoimmune conditions, breaks down into byproducts that irritate the bladder lining. External beam radiation directed at the pelvis, often used for cervical, prostate, or rectal cancers, can also damage bladder tissue and increase cancer risk years after treatment.
If you’ve had either of these treatments, your oncologist likely factors this into long-term monitoring. The time between treatment and a potential bladder cancer diagnosis can be many years, so awareness of this connection matters even well after the original treatment ends.
Genetics and How Your Body Handles Carcinogens
Some people are genetically less efficient at breaking down the cancer-causing chemicals found in tobacco smoke and industrial exposures. Two enzyme families play a central role. One group helps deactivate toxic compounds from tobacco smoke; certain inherited gene variants result in a complete loss of this enzyme activity, leaving those individuals more vulnerable. A second group of enzymes determines how quickly your body processes these carcinogens. People with “slow” versions of these enzymes keep harmful chemicals circulating in their system longer, giving those chemicals more time to damage the bladder lining.
These genetic differences help explain why some smokers develop bladder cancer while others do not. They also interact with occupational exposures. Lynch syndrome, a hereditary condition that raises the risk of several cancers, is also recognized as a risk factor for bladder cancer.
A Diabetes Medication Linked to Risk
Pioglitazone, a medication used to manage type 2 diabetes, has been associated with a modest increase in bladder cancer risk. A large population-based study published in The BMJ found that people taking pioglitazone had about 63% higher risk compared to those using other diabetes medications. The risk increased with longer use: people who took it for more than two years had a 78% higher risk. A related drug in the same class, rosiglitazone, did not show this association, suggesting the risk is specific to pioglitazone rather than the entire drug category.
To put these numbers in perspective, the absolute rates were 121 cases per 100,000 person-years for pioglitazone users versus 89 per 100,000 for users of other diabetes drugs. That translates to roughly 32 additional cases per 100,000 people per year, a meaningful but not dramatic increase in absolute terms.
Why Early Detection Matters
The stakes of knowing your risk factors become clearer when you look at survival rates. Bladder cancer caught while still confined to the bladder has a 71% five-year survival rate. Once it spreads to distant parts of the body, that drops to 8%. Blood in the urine, even if painless and intermittent, is the most common early warning sign. If you carry multiple risk factors, paying attention to urinary changes and reporting them promptly can make a significant difference in outcomes.